French pharmaceutical company Sanofi has released new data for its top-selling diabetes drug Lantus, which shows that the insulin treatment is much more efficient than other forms of care in helping patients meet blood sugar targets.
In a statement, the drugmaker said Lantus proved three times more likely to reach and maintain glycemic target levels in patients with pre-diabetes or early type 2 diabetes at high risk of heart disease, compared to standard care .
The positive result was based on a six-year clinical trial called ORIGIN, which focused on the care of more than 12,500 pre-diabetic or type 2 diabetic patients.
Riccardo Perfetti, vice-president of medical affairs, global diabetes, at Sanofi, said the research contradicts conventional understanding that diabetes is a progressively worsening disease, as it suggests that Lantus could control the metabolic condition.
Lantus currently holds an 80 per cent share of the global market for long-acting (basal) insulins for the treatment of diabetes .
Sales of the product fell just short of 4 billion euros last year, representing 12 per cent of Sanofi’s total annual revenue, and sales of shown no signs of slowing down this year, with Sanofi posting double-digit percentage sales growth in the second quarter.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…